Skip to Main Content

COVID-19 is an emerging, rapidly evolving situation.

What people with cancer should know: https://www.cancer.gov/coronavirus

Get the latest public health information from CDC: https://www.coronavirus.gov

Get the latest research information from NIH: https://www.nih.gov/coronavirus

About this Publication
Title
Performance of Lung-RADS in the National Lung Screening Trial: A Retrospective Assessment.
Pubmed ID
25664444 (View this publication on the PubMed website)
Publication
Ann. Intern. Med. 2015 Feb; Volume [Epub ahead of print]: Pages [Epub ahead of print]
Authors

Pinsky PF, Gierada DS, Black W, Munden R, Nath H, Aberle D, Kazerooni E

Abstract

BACKGROUND: Lung cancer screening with low-dose computed tomography (LDCT) has been recommended, based primarily on the results of the NLST (National Lung Screening Trial). The American College of Radiology recently released Lung-RADS, a classification system for LDCT lung cancer screening.

OBJECTIVE: To retrospectively apply the Lung-RADS criteria to the NLST.

DESIGN: Secondary analysis of a group from a randomized trial.

SETTING: 33 U.S. screening centers.

PATIENTS: Participants were randomly assigned to the LDCT group of the NLST, were aged 55 to 74 years, had at least a 30-pack-year history of smoking, and were current smokers or had quit within the past 15 years.

INTERVENTION: 3 annual LDCT lung cancer screenings.

MEASUREMENTS: Lung-RADS classifications for LDCT screenings. Lung-RADS categories 1 to 2 constitute negative screening results, and categories 3 to 4 constitute positive results.

RESULTS: Of 26 722 LDCT group participants, 26 455 received a baseline screening; 48 671 screenings were done after baseline. At baseline, the false-positive result rate (1 minus the specificity rate) for Lung-RADS was 12.8% (95% CI, 12.4% to 13.2%) versus 26.6% (CI, 26.1% to 27.1%) for the NLST; after baseline, the false-positive result rate was 5.3% (CI, 5.1% to 5.5%) for Lung-RADS versus 21.8% (CI, 21.4% to 22.2%) for the NLST. Baseline sensitivity was 84.9% (CI, 80.8% to 89.0%) for Lung-RADS versus 93.5% (CI, 90.7% to 96.3%) for the NLST, and sensitivity after baseline was 78.6% (CI, 74.6% to 82.6%) for Lung-RADS versus 93.8% (CI, 91.4% to 96.1%) for the NLST.

LIMITATION: Lung-RADS criteria were applied retrospectively.

CONCLUSION: Lung-RADS may substantially reduce the false-positive result rate; however, sensitivity is also decreased. The effect of using Lung-RADS criteria in clinical practice must be carefully studied.

PRIMARY FUNDING SOURCE: National Institutes of Health.

Related CDAS Studies
Related CDAS Projects